Synergistic Tissue Kallikrein 1 Systems for Personalized Ischemic Condition Treatment
Legal Citation
Summary of the Inventive Concept
This inventive concept integrates dosage forms of tissue kallikrein 1 with distinct technologies such as AI, IoT, blockchain, and nanomaterials to create a more powerful system for treating ischemic conditions, enabling personalized dosage optimization, real-time monitoring, and secure data storage.
Background and Problem Solved
The original patent disclosed dosage forms of tissue kallikrein 1 for treating ischemic conditions, but it had limitations in terms of personalized treatment and data management. This inventive concept addresses these limitations by combining the patented dosage forms with advanced technologies to create a more effective and efficient system.
Detailed Description of the Inventive Concept
The system comprises a dosage form of tissue kallikrein 1, an artificial intelligence module for personalized dosage optimization, IoT-enabled sensors for real-time monitoring, a blockchain-based decentralized data storage module for secure storage and sharing of medical records, and a nanomaterial-based sensor array for wearable devices. The AI module analyzes patient data and optimizes dosage, while the IoT sensors track treatment efficacy and the blockchain module ensures secure data storage. The wearable device enables real-time monitoring, and the nanomaterial-based sensor array enhances sensitivity and accuracy.
Novelty and Inventive Step
The new claims introduce the synergistic combination of dosage forms of tissue kallikrein 1 with AI, IoT, blockchain, and nanomaterials, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a more powerful system for treating ischemic conditions.
Alternative Embodiments and Variations
Alternative embodiments may include integrating the dosage forms with other AI algorithms, using different IoT sensors or blockchain platforms, or incorporating other nanomaterials or wearable devices. Variations may include using the system for treating other conditions, such as cancer or inflammatory diseases.
Potential Commercial Applications and Market
This inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine, telemedicine, and digital health. The target market includes hospitals, clinics, and research institutions, as well as patients and healthcare providers.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/4853 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K45/06 |
| C | C12 | C12Y304/21035 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically focused on tissue kallikrein 1 (KLK1) dosage forms for treating ischemic conditions, involving drug delivery systems, personalized medicine technologies, and medical monitoring techniques
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or pharmaceutical scientist with expertise in protein therapeutics, drug delivery systems, medical device integration, and digital health technologies, holding advanced degrees and practical experience in translating biological research into clinical applications
Obviousness Rationale
A PHOSITA would recognize that integrating digital health technologies with existing therapeutic approaches represents a natural progression in personalized medicine. The combination of KLK1 dosage forms with AI, IoT, and monitoring technologies follows established patterns of technological convergence in medical treatment. The disclosed variations represent predictable extensions of known techniques for enhancing therapeutic monitoring and personalization.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,608 |
|---|---|
| Title | Dosage forms of tissue kallikrein 1 |
| Assignee(s) | DiaMedica Inc. |